Industrials [ 10/12 ] | Machinery [ 54/74 ]
NYSE | Common Stock
Mirion Technologies, Inc. provides radiation detection, measurement, analysis, and monitoring products and services in North America, Europe, and the Asia Pacific.
It operates in two segments, Medical, and Nuclear & Safety.
The Medical segment offers radiation oncology quality assurance and dosimetry solutions; patient safety solutions for diagnostic imaging and radiation therapy centers; radiation therapy quality assurance solutions for calibrating and verifying imaging and treatment accuracy; and radionuclide therapy products for nuclear medicine applications, such as product handling, medical imaging furniture, and rehabilitation products.
This segment improves the quality and safety of cancer care delivery; and supports applications across medical diagnostics and practitioner safety.
The Nuclear & Safety segment focuses on addressing critical radiation safety, measurement, and analysis applications; and provides personal radiation detection, identification equipment, and analysis tools.
The company's products and solutions also include radiation measurement and monitoring solutions, reactor instrumentation and control detectors, imaging systems and cameras, and waste management systems; laboratory and scientific analysis systems comprising gamma/alpha spectroscopy, alpha/beta counting, specialty detectors, and spectroscopy software; radiation measurement and health physics instrumentation; and contamination and clearance monitors.
It serves hospitals, clinics and urgent care facilities, dental and veterinary offices, radiation treatment facilities, OEMs for radiation therapy, laboratories, military organizations, government agencies, industrial companies, power and utility companies, reactor design firms, and NPPs.
The company was formerly known as Global Monitoring Systems, Inc. and changed its name to Mirion Technologies, Inc. in January 2006.
Mirion Technologies, Inc. was incorporated in 2005 and is headquartered in Atlanta, Georgia.
| Reported date | EPSChange YoY | EstimateSurprise |
|---|---|---|
| Feb 11, 25 | 0.17 Increased by +13.33% | 0.15 Increased by +15.10% |
| Oct 29, 24 | 0.08 Increased by +60.00% | 0.09 Decreased by -11.11% |
| Aug 1, 24 | 0.10 Increased by +25.00% | 0.08 Increased by +25.00% |
| Apr 30, 24 | 0.06 Increased by 0.00% | 0.06 |
| Feb 13, 24 | 0.15 Increased by +36.36% | 0.14 Increased by +7.14% |
| Nov 1, 23 | 0.05 Increased by +66.67% | 0.05 |
| Aug 2, 23 | 0.08 Decreased by -38.46% | 0.06 Increased by +33.33% |
| May 3, 23 | 0.06 Decreased by -40.00% | 0.05 Increased by +20.00% |
| Fiscal ending date | RevenueChange YoY | IncomeChange YoY | ProfitChange YoY |
|---|---|---|---|
| Dec 31, 24 | 254.30 M Increased by +10.37% | 15.00 M Increased by +198.68% | Increased by +5.90% Increased by +189.41% |
| Sep 30, 24 | 206.80 M Increased by +8.16% | -13.60 M Decreased by -12.40% | Decreased by -6.58% Decreased by -3.92% |
| Jun 30, 24 | 207.10 M Increased by +5.02% | -11.70 M Increased by +57.76% | Decreased by -5.65% Increased by +59.78% |
| Mar 31, 24 | 192.60 M Increased by +5.77% | -25.80 M Increased by +42.79% | Decreased by -13.40% Increased by +45.91% |
| Dec 31, 23 | 230.40 M Increased by +5.74% | -15.20 M Increased by +90.68% | Decreased by -6.60% Increased by +91.19% |
| Sep 30, 23 | 191.20 M Increased by +18.83% | -12.10 M Increased by +79.97% | Decreased by -6.33% Increased by +83.14% |
| Jun 30, 23 | 197.20 M Increased by +12.17% | -27.70 M Increased by +52.73% | Decreased by -14.05% Increased by +57.86% |
| Mar 31, 23 | 182.10 M Increased by +11.58% | -45.10 M Decreased by -65.81% | Decreased by -24.77% Decreased by -48.60% |